These data indicate that the dual targeting of the fractalkine receptor and poly(ADP-ribose) polymerase can offer a new therapeutic approach and potentially extend the use of poly(ADP-ribose) polymerase inhibitors to most cases of high-grade serous carcinoma, irrespective of their homologous recombination capacity. Here, CX3CR1 is linked to serous adenocarcinoma.